JP6469015B2 - エネルギー代謝を増大させるための組成物および方法 - Google Patents

エネルギー代謝を増大させるための組成物および方法 Download PDF

Info

Publication number
JP6469015B2
JP6469015B2 JP2015542039A JP2015542039A JP6469015B2 JP 6469015 B2 JP6469015 B2 JP 6469015B2 JP 2015542039 A JP2015542039 A JP 2015542039A JP 2015542039 A JP2015542039 A JP 2015542039A JP 6469015 B2 JP6469015 B2 JP 6469015B2
Authority
JP
Japan
Prior art keywords
composition
leucine
subject
sildenafil
hmb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015542039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537002A5 (enExample
JP2015537002A (ja
Inventor
マイケル ジメル，
マイケル ジメル，
アンチェ ブルックバウアー，
アンチェ ブルックバウアー，
ブルック バゲット，
ブルック バゲット，
Original Assignee
ニューサート サイエンシーズ， インコーポレイテッド
ニューサート サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューサート サイエンシーズ， インコーポレイテッド, ニューサート サイエンシーズ， インコーポレイテッド filed Critical ニューサート サイエンシーズ， インコーポレイテッド
Publication of JP2015537002A publication Critical patent/JP2015537002A/ja
Publication of JP2015537002A5 publication Critical patent/JP2015537002A5/ja
Application granted granted Critical
Publication of JP6469015B2 publication Critical patent/JP6469015B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2015542039A 2012-11-13 2013-11-13 エネルギー代謝を増大させるための組成物および方法 Expired - Fee Related JP6469015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726006P 2012-11-13 2012-11-13
US61/726,006 2012-11-13
PCT/US2013/069957 WO2014078459A1 (en) 2012-11-13 2013-11-13 Compositions and methods for increasing energy metabolism

Publications (3)

Publication Number Publication Date
JP2015537002A JP2015537002A (ja) 2015-12-24
JP2015537002A5 JP2015537002A5 (enExample) 2016-12-28
JP6469015B2 true JP6469015B2 (ja) 2019-02-13

Family

ID=50731663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542039A Expired - Fee Related JP6469015B2 (ja) 2012-11-13 2013-11-13 エネルギー代謝を増大させるための組成物および方法

Country Status (14)

Country Link
US (3) US9943517B2 (enExample)
EP (1) EP2919772B1 (enExample)
JP (1) JP6469015B2 (enExample)
KR (1) KR20150082623A (enExample)
CN (3) CN104918610B (enExample)
AU (2) AU2013344753B2 (enExample)
BR (1) BR112015010947A2 (enExample)
CA (1) CA2891335C (enExample)
IL (1) IL238726B (enExample)
MX (1) MX2015006023A (enExample)
PH (1) PH12015501062A1 (enExample)
RU (1) RU2655794C2 (enExample)
SG (2) SG11201503774PA (enExample)
WO (1) WO2014078459A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841748C (en) 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
CN104918610B (zh) 2012-11-13 2018-04-10 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo
WO2016081035A1 (en) * 2014-11-21 2016-05-26 Schoenwetter Phillip E Novel antioxidant formulations
CN107427488A (zh) * 2014-12-19 2017-12-01 光环生命科学有限公司 鞣花酸二水合物在食品和保健品中的用途
US20160346238A1 (en) * 2015-06-01 2016-12-01 Metabolic Technologies, Inc. Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass
CA2996386C (en) 2015-08-28 2023-10-03 AlgaHealth (AH) Ltd. Improved process for producing fucoxanthin and/or polysaccharides from microalgae
CN106854643B (zh) * 2015-12-08 2021-01-26 台湾粒线体应用技术股份有限公司 植物萃取物用于提升粒线体活性的用途
JP6718470B2 (ja) * 2016-01-25 2020-07-08 サントリーホールディングス株式会社 エラグ酸ゼラチンカプセルを含有する組成物
WO2017205673A1 (en) 2016-05-25 2017-11-30 TSI Group Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
CN105920057A (zh) * 2016-06-03 2016-09-07 通化师范学院 一种淫羊藿苷的用途
CN108144062A (zh) * 2017-12-15 2018-06-12 上海交通大学医学院 调控senp1磷酸化修饰化合物和sirt3 sumo化修饰化合物及其应用
KR102082041B1 (ko) * 2018-03-30 2020-02-26 건국대학교 산학협력단 에피갈로카테킨 갈레이트 프로드러그, 이의 제조방법 및 이를 포함하는 미토콘드리아 생합성 촉진용 조성물
US11819535B2 (en) * 2018-06-14 2023-11-21 University Health Network Composition and methods for regulating extracellular matrix accumulation
KR102267472B1 (ko) * 2018-10-24 2021-06-21 전남대학교산학협력단 녹차 카테킨을 포함하는 중성지방 저감용 식품 조성물, 대사성 질환 개선용 식품 조성물 및 대사성 질환 예방 또는 치료용 약학 조성물
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
KR102068299B1 (ko) * 2018-12-21 2020-01-20 한국기초과학지원연구원 Cyp4a 저해 화합물을 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4001158A1 (fr) * 2020-11-18 2022-05-25 Eric Favre Dispositif bouchon pour bouteilles
CA3214950A1 (en) 2021-04-07 2022-10-13 Ralf Jager 1-methylxanthine-based bioactive composition and method of use thereof
WO2022251683A1 (en) * 2021-05-27 2022-12-01 Allen Gregory Seth Weight loss formulation and methods
WO2023064425A1 (en) * 2021-10-12 2023-04-20 Ingenious Ingredients, LP Dileucine compositions and methods of use thereof for fat loss
CN115181721A (zh) * 2022-07-13 2022-10-14 山东省农业科学院畜牧兽医研究所 一种抑制肉羊皮下脂肪细胞增殖和脂肪合成代谢的方法
AU2023413146A1 (en) * 2022-12-21 2025-07-31 Px Ing, Llc Bioactive compositions and methods of use thereof
WO2024186730A1 (en) * 2023-03-03 2024-09-12 Grads Innovation Compositions for enhanced metabolic oxidation of fatty acids

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
EP0873754B1 (en) 1996-01-09 2003-07-30 Riken Amino acid compositions
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
PT862863E (pt) 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
WO1999057124A1 (en) 1998-05-04 1999-11-11 Andreas Johannes Kesel Monomeric, oligomeric and polymeric knoevenagel condensation products
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
BR0008857A (pt) 1999-03-08 2001-12-18 Medicure Inc Análogos de piridoxal para distúrbios da vitaminab-6
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
CN1303671A (zh) * 1999-11-26 2001-07-18 深圳市御康实业有限公司湖南省分公司 肉桂酸用于制备治疗糖尿病的药物
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
CA2399319A1 (en) 2000-01-25 2001-08-16 Nathan D. Hamilton Nutritional supplements for aged pets
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
CA2538758C (en) 2000-06-16 2014-10-28 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
JP2002047699A (ja) 2000-07-31 2002-02-15 Toto Ltd 給水の配管システム
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
KR20030023747A (ko) * 2000-08-11 2003-03-19 화이자 인코포레이티드 인슐린 저항성 증후군의 치료
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
TWI329516B (en) 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
US6517877B2 (en) 2000-12-29 2003-02-11 Martin Francis Gannon Animal food product
MXPA03007802A (es) 2001-03-09 2003-12-08 Nestle Sa Composicion que mejora las deficiencias fisiologicas relacionadas con la edad y que incrementa la longevidad.
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
US20060110478A1 (en) * 2004-11-22 2006-05-25 Mccleary Edward L Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction
JP3591492B2 (ja) * 2001-07-18 2004-11-17 日本電気株式会社 パケット振分装置およびパケット振分プログラム
IL161430A0 (en) 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
EP1525323B1 (en) 2001-11-09 2015-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1beta, a novel pgc-1 homologue and uses therefor
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
US20040009216A1 (en) 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
EP2301537A1 (en) 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20050181097A1 (en) 2002-09-16 2005-08-18 Mars, Inc. Nutritionally complete pet food and method of feeding and manufacturing same
RU2335927C2 (ru) 2002-09-20 2008-10-20 Новартис Аг Обогащенные лейцином питательные композиции
EP1551281A4 (en) 2002-10-09 2007-11-21 Bodymedia Inc METHOD AND DEVICE FOR AUTOMATIC RECORDING OF CONTINUOUS OR DISCRETE BODY STATES BASED ON PHYSIOLOGICAL AND / OR CONTEXT PARAMETERS
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
WO2004082401A1 (en) 2003-03-13 2004-09-30 Red Arrow Products Co., Llc. Browning composition for application to a film for holding a food product
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
WO2004082667A1 (en) * 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
RU2356247C2 (ru) 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
DE602004012745T2 (de) 2003-05-14 2009-04-09 Indus Biotech Pvt. Ltd. Synergistische zusammensetzung zur behandlung von diabetes mellitus
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
FR2856407B1 (fr) 2003-06-19 2007-10-12 Inst Nat Sante Rech Med Procede de production d'une proteine recombinante d'interet et proteine produite
US20080024272A1 (en) * 2003-07-18 2008-01-31 Fiske Michael S Biometric authentication lock machine
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
EP2319410A1 (en) 2003-09-12 2011-05-11 BodyMedia, Inc. Apparatus for measuring heart related parameters
CA2544078C (en) 2003-11-03 2013-08-06 Hill's Pet Nutrition, Inc. Coated pet food composition
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
EP1685833A1 (en) 2003-11-21 2006-08-02 Ajinomoto Co., Inc. Remedy for diabetes
AU2004294986B2 (en) 2003-11-26 2010-09-09 Hill's Pet Nutrition, Inc. Method to reduce stool odor of companion animals
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
CN1968684A (zh) 2004-06-17 2007-05-23 森林实验室公司 美金刚的调释制剂
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
WO2006013750A1 (ja) 2004-08-04 2006-02-09 Tokyo University Of Marine Science And Technology 脂質代謝調節作用を有する食品素材、健康食品、動物用飼料及び動物の飼育方法
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
EP3326543B1 (en) 2004-08-24 2019-07-24 DePuy Mitek, LLC Expandable needle suture apparatus and associated handle assembly with rotational suture manipulation system
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
CN1287801C (zh) * 2004-10-29 2006-12-06 杨世杰 治疗前列腺炎的药物组合物
EP1818055A1 (en) 2004-11-29 2007-08-15 Toyo Shinyaku Co., Ltd. Athletic ability enhancing composition
EP1832284A4 (en) 2004-12-28 2008-07-30 Ajinomoto Kk INDUCER OR SECRETAGOGUE OF ADIPONECTIN
JP2008527020A (ja) * 2005-01-18 2008-07-24 ディーエスエム アイピー アセッツ ビー．ブイ． 新規な栄養補助組成物
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
PT1845994E (pt) 2005-02-11 2009-04-13 Argenta Discovery Ltd Combinação de compostos de metilxantina e esteróides para tratar doenças respiratórias crónicas
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
AU2006218404A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
PT1890709E (pt) 2005-05-13 2012-02-06 Nestec Sa Produção de glucosamina a partir de espécies de plantas
CA2607600A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
WO2007008548A2 (en) 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007039367A (ja) 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2431050T3 (es) 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007041641A1 (en) 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
CA2631647A1 (en) 2005-11-30 2007-06-07 Nestec S.A. Use of branched-chain amino acids for the treatment of muscle loss
CA2631401C (en) 2005-12-02 2013-01-29 Hill's Pet Nutrition, Inc. Methods for altering stool quality and/or stool frequency
US20090136588A1 (en) 2005-12-02 2009-05-28 Hill's Pet Nutrition, Inc. Methods For Altering Food Intake, Modifying Nutrient Digestibility and Altering Stool Quality and/or Stool Frequency
JPWO2007069744A1 (ja) 2005-12-16 2009-05-28 味の素株式会社 メタボリックシンドローム予防・改善用組成物
CA2635655C (en) 2006-01-10 2011-09-06 Hill's Pet Nutrition, Inc. Compositions and methods for promoting fat loss
CA2644046A1 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Metabolic regulators and uses thereof
JP5222482B2 (ja) 2006-04-07 2013-06-26 花王株式会社 脂肪分解促進剤
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
US20090182036A1 (en) 2006-05-10 2009-07-16 Krammer-Lukas Stephanie J M Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP2008063328A (ja) 2006-08-07 2008-03-21 Kowa Co 糸球体疾患治療剤
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
CA2672420A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
EP2494967A1 (en) 2007-01-16 2012-09-05 Ipintl, Llc Novel composition for treating metabolic syndrome
US20080319855A1 (en) 2007-02-16 2008-12-25 Stivoric John M Advertising and marketing based on lifeotypes
WO2008103179A1 (en) 2007-02-23 2008-08-28 Hill's Pet Nutrition, Inc. Compositions and methods for controlling the weight of animals
US20080233245A1 (en) 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance
US7850997B2 (en) 2007-03-21 2010-12-14 Tim Romero Dietary compositions and methods of enhancing lean body mass and exercise performance
US20080242727A1 (en) * 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
JP2010526781A (ja) 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤
US20080286254A1 (en) 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
JP5121308B2 (ja) 2007-05-28 2013-01-16 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善または治療組成物
US20100204204A1 (en) 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
US20090054450A1 (en) 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
US8088043B2 (en) 2007-09-07 2012-01-03 Nike, Inc. Wearable device assembly having athletic functionality
US7820618B2 (en) 2007-10-04 2010-10-26 Northern Innovations and Formulations Energy status of an individual by enhanced usage of an endogenous fuel source
US20090104312A1 (en) 2007-10-22 2009-04-23 Kamarei A Reza Neutralized juice-based beverages and method of making same
US20110082189A1 (en) 2007-10-23 2011-04-07 President And Fellows Of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
US20100304003A1 (en) 2007-12-21 2010-12-02 Kim Friesen Pet food composition
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MY158994A (en) 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
CN101978374A (zh) 2008-03-03 2011-02-16 耐克国际有限公司 交互式运动设备系统
CA2716923A1 (en) 2008-03-17 2009-09-24 The Procter & Gamble Company User-customizable dosing system
EP2265341A1 (en) 2008-04-02 2010-12-29 Nike International Ltd. Wearable device assembly having athletic functionality
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
US7968431B2 (en) * 2008-07-15 2011-06-28 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
CN106173266A (zh) 2008-07-18 2016-12-07 希尔氏宠物营养品公司 治疗与体重过重动物相关的疾病的组合物和方法
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
RU2513133C2 (ru) 2008-08-15 2014-04-20 Нестек С.А. Способы усиления энергетического обмена
FR2938732B1 (fr) 2008-11-21 2011-04-01 Holymark Composition nutritive pour sportif, en particulier pour pratiquant d'une activite physique superieure a une heure.
CA2745376A1 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
US8562489B2 (en) 2009-04-26 2013-10-22 Nike, Inc. Athletic watch
BRPI1012779B1 (pt) 2009-05-28 2021-06-01 Mars, Incorporated Alimento para animais de estimação sob a forma de péletes de ração revestidos
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
CN102573496B (zh) 2009-07-01 2015-08-26 玛格塞蒂克斯公司 缓释镁组合物及其用途
CN102469812A (zh) 2009-07-21 2012-05-23 希尔氏宠物营养品公司 陪伴动物营养系统
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
WO2011035179A1 (en) 2009-09-18 2011-03-24 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
US9173422B2 (en) 2009-12-29 2015-11-03 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
MX340938B (es) 2010-01-06 2016-08-01 Nestec Sa Regimenes dieteticos utiles para imitar la restriccion calorica.
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
WO2011136159A1 (ja) 2010-04-28 2011-11-03 日本薬品株式会社 眼精疲労治療用組成物
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
CN102228521A (zh) * 2011-06-29 2011-11-02 田景振 一种治疗早中期糖尿病肾病的中药新药
CA2841748C (en) 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
AU2012299126B2 (en) 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
CN104918610B (zh) 2012-11-13 2018-04-10 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
EP2968206A4 (en) 2013-03-15 2016-09-21 Nusirt Sciences Inc TREATMENT OF PETS WITH SIRTUIN ACTIVATORS
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
EP3054940B1 (en) 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2016049236A1 (en) 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
WO2017040407A1 (en) 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Also Published As

Publication number Publication date
MX2015006023A (es) 2016-03-31
CN104918610B (zh) 2018-04-10
SG11201503774PA (en) 2015-06-29
US9943517B2 (en) 2018-04-17
CN108295058A (zh) 2018-07-20
US20180235970A1 (en) 2018-08-23
CA2891335C (en) 2021-05-04
CN104918610A (zh) 2015-09-16
AU2018264157A1 (en) 2018-12-06
AU2013344753B2 (en) 2018-09-27
US20200338078A1 (en) 2020-10-29
PH12015501062A1 (en) 2015-08-17
KR20150082623A (ko) 2015-07-15
US20160279130A1 (en) 2016-09-29
EP2919772A1 (en) 2015-09-23
US10646489B2 (en) 2020-05-12
CA2891335A1 (en) 2014-05-22
IL238726B (en) 2020-02-27
EP2919772B1 (en) 2019-03-27
WO2014078459A1 (en) 2014-05-22
EP2919772A4 (en) 2016-06-08
RU2015122755A (ru) 2017-01-10
RU2655794C2 (ru) 2018-05-29
BR112015010947A2 (pt) 2018-06-05
IL238726A0 (en) 2015-06-30
AU2013344753A1 (en) 2015-06-04
JP2015537002A (ja) 2015-12-24
CN108452311A (zh) 2018-08-28
HK1212594A1 (en) 2016-06-17
SG10201709195TA (en) 2017-12-28

Similar Documents

Publication Publication Date Title
JP6469015B2 (ja) エネルギー代謝を増大させるための組成物および方法
US10383837B2 (en) Compositions and methods for modulating metabolic pathways
US9724319B2 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
HK1212594B (en) Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190115

R150 Certificate of patent or registration of utility model

Ref document number: 6469015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees